ALCOHOLIC HEPATITIS TREATMENT MARKET ANALYSIS
Moreover, increasing product launches and approvals is expected to boost global alcoholic hepatitis treatment market growth. For instance, on December 16, 2020, Durect Corporation announced that DUR-928 was granted fast track designation by the U.S. Food and Drug Administration (FDA) for the treatment of alcoholic hepatitis. Durect is a biopharmaceutical company dedicated to transforming the treatment of acute organ injury and chronic liver diseases through the development of novel, potentially lifesaving therapies. DUR-928, Durect's lead drug candidate, is an endogenous sulfated oxysterol and an epigenetic regulator with a distinct mechanism of action. Epigenetic regulators are compounds that control gene expression patterns without altering the DNA sequence. These factors are expected to support global alcoholic hepatitis treatment market growth over the forecast period.
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India : 